THE MONSANTO BILL is eight years old and still unpaid

THE MONSANTO BILL is eight years old and still unpaid. When Bayer acquired the American agrochemical company in 2018, the deal was sold as a transformation into a seeds-and-traits powerhouse. What management did not foresee, or chose not to price, was a wave of litigation alleging that Monsanto's Roundup weedkiller causes cancer. The lawsuits have been a cash vacuum, a distraction, and a drag on the share price. On August 4th, the German life-sciences giant presented its second-quarter results. The operating businesses are growing. The balance sheet is being rearranged to survive the remainder of the drain. The question is whether the exit is finally in sight or whether the bill has merely been refinanced.

The numbers themselves are respectable. Group sales rose 2% on a currency- and portfolio-adjusted basis to €10.9 billion in the quarter and 3% for the first half to €24.3 billion. EBITDA before special items (a cash-earnings proxy that excludes depreciation, interest and tax) grew 2% in the quarter and 7% in the first half. Crop Science, the division that gave the acquisition its strategic rationale, grew sales 3.5% in the quarter to €4.9 billion and expanded its EBITDA margin to 31%. The return of the dicamba herbicide label in America - suspended by a federal court in 2024 - helped: soybean-seed sales rose 17% and cotton-seed sales jumped 69%. Pharmaceuticals was flat overall, though the launch drugs NUBEQA and KERENDIA together grew 66%, offsetting erosion in Xarelto and a 27% fall in Eylea as biosimilar competitors capture market share. Consumer Health added 3.5%, with nutritionals and dermatology pulling their weight. This is not the performance of a company in retreat.

The trouble is cash. Free cash flow turned negative in the quarter at €371 million and was negative €2.7 billion for the first half, more than double the drain a year earlier. Management attributes €2.5 billion of that to litigation-related payouts. The core-earnings-per-share figure for the quarter fell 17% to €0.95, which management described as a normalisation after one-off tax and reconciliation benefits in the prior year. The phrasing is careful. What it means is that the underlying business is roughly intact; it is the legal tail that makes the headline volatile.

That tail is the subject of a multi-pronged containment strategy that has, at long last, begun to show signs of a pincer. In June the Supreme Court ruled in Bayer's favour in Monsanto v. Durnell, a case on whether state failure-to-warn claims are preempted by federal law, since the EPA has approved glyphosate labels without requiring a cancer warning. The ruling makes it harder for plaintiffs to bring new suits. In July, Monsanto - which remains a Bayer subsidiary - announced a proposed nationwide class settlement totalling up to $7.25 billion, payable in declining installments over 21 years. Together, the settlement and the ruling are independently necessary, as management put it. The Court narrows the legal theory; the settlement caps the financial exposure. Bayer has raised its litigation provisions from €7.8 billion to €11.8 billion and expects about €5 billion in payouts this year. The company also settled eight remaining PCB verdicts from an environmental contamination case dating to chemicals Monsanto stopped producing in 1977. One does not have to endorse the EPA's safety conclusions to appreciate the strategic arithmetic. The company is paying a known sum over a known period rather than facing an unbounded stream of jury verdicts.

To be sure, €11.8 billion in provisions is a large number, and the $7.25 billion settlement is not cheap. The settlement still requires court approval. The Supreme Court ruling does not dismiss existing cases. What the containment strategy does is change the character of the risk: from open-ended litigation to a managed payment stream. That matters because markets price uncertainty far more harshly than they price known liabilities.

The balance-sheet gymnastics to fund the interim gap are revealing. In July, Bayer secured €3 billion in equity from Apollo Global Management, a private-asset manager, for a minority, non-controlling stake in its long-acting reversible contraceptives business. The contraceptives unit - a stable, growing cash cow - will remain fully consolidated in Bayer's accounts and under its operational control. The transaction, which is expected to close in the third quarter, is not a strategic sale. It is closer to a secured loan dressed as equity. Apollo gets a claim on a predictable business; Bayer gets cash without diluting existing shareholders or weakening its credit rating. The deal lowers the company's year-end net-debt target from €32-33 billion to €29-30 billion. Management also issued $5 billion of dollar bonds to cover maturities and litigation outflows. The aim is to survive the cash hole of 2026 and emerge with a manageable balance sheet. It is clever, but it is also a signal that the company cannot simply wait for operating cash flow to solve the problem.

The deeper question for investors is whether the operating businesses can grow fast enough to make the litigation overhang a footnote rather than a defining feature. Crop Science's margin expansion is impressive - 31% is a strong return for a commodity-adjacent business - but it runs into headwinds. Glyphosate, one of the lowest-margin products in the portfolio, has been consolidated into a separate entity called Ruvion, presumably to make it easier to manage or eventually spin off. Volume phasing in seeds and weather sensitivity in crop protection mean the division is not an automatic growth engine. Pharmaceuticals has genuine growth stories: NUBEQA (a prostate-cancer treatment) and KERENDIA (for kidney disease) are scaling quickly, and the blood thinner asundexian has received priority review in America and China with a planned launch in late 2026 or early 2027. But Xarelto, once the crown jewel, continues to decline, and Eylea is being eroded by biosimilars at a pace that the higher-dose formulation cannot fully offset. The pipeline is credible but not yet transformative.

It is tempting to read the quarter as a turning point and call the turnaround complete. The operating businesses are growing, the Supreme Court has ruled in Bayer's favour, and a class settlement is in the pipeline. A wiser reading recognises that the company is still in the middle of a long and expensive process of untying itself from a bad acquisition. The Apollo deal is evidence of that: a blue-chip company selling a minority stake in one of its own businesses to pay for the consequences of an acquisition made nearly a decade ago is not the behaviour of a firm at full strength. It is the behaviour of a firm doing what it must.

For investors, the relevant risk is not the operating businesses, which are showing disciplined growth, but the timing of the exit. If the class settlement gains court approval and the Supreme Court precedent limits future filings, the litigation overhang will shrink materially by the end of 2026. The share price, which rose roughly 5% on the results, is already pricing some of that relief. But the gap between known cash outflows this year and the point at which free cash flow turns positive again will be measured in quarters, not months. Until then, the company is earning its growth while simultaneously paying for its past. That is a structure that rewards patience but punishes impatience.

The broader lesson is one that corporate acquirers ought to remember: integration risk is not merely cultural. It is legal, regulatory and financial. Bayer's management has been systematic rather than heroic in its response - settlements, a Court appeal, balance-sheet engineering, operational consolidation. Whether that is enough depends on the speed of resolution. The better answer, had it been available in 2018, would have been to price the litigation risk into the deal. Now the aim is to price it out.